[(4S,5R)-4-氟-5-(6-甲基氨基嘌呤-9-基)四氢呋喃-2-基]甲醇 | 126502-17-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: [(4S,5R)-4-氟-5-(6-甲基氨基嘌呤-9-基)四氢呋喃-2-基]甲醇
• 中文别名: 1H-1,2,4-三唑,3-(1,1-二甲基乙基)-5-[(1,3-二噁戊环-2-基甲基)硫代]-
• 英文名称: N⁶-methyl-9-(2',3'-dideoxy-2'-fluoro-β-D-arabinofuranosyl)adenine
• 英文别名: 6-(methylamino)-9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)-9H-purine；N⁶-methyl-9-(2,3-dideoxy-2-fluoro-β-D-arabinofuranosyl)adenine；9-(2,3-Dideoxy-2-fluoro-β-D-arabinofuranosyl)-6-(methylamino)purine；Fmadda；[(2S,4S,5R)-4-fluoro-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methanol
• CAS: 126502-17-8
• 化学式: C₁₁H₁₄FN₅O₂
• 分子量: 267.263
• InChiKey: BBUZAEMTTVCRAD-OKTBNZSVSA-N

物化性质

• 沸点：
  526.0±60.0 °C(Predicted)
• 密度：
  1.67±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  85.1
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [(4S,5R)-4-氟-5-(6-甲基氨基嘌呤-9-基)四氢呋喃-2-基]甲醇 以100%的产率得到9-[(2R,3S,5S)-3-氟-5-(羟基甲基)四氢呋喃-2-基]-3H-嘌呤-6-酮
  参考文献：
  名称：

  Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs

  摘要：

  Selected acid-stable (2'-fluoro-2',3'-dideoxyarabinofuranosyl)adenine nucleosides containing methyl groups and other lipophilic functions at various positions in the adenine ring were prepared and evaluated as anti-HIV agents. The N6-methyl (1f), N6-benzoyl (1g), and 6-chloro (li) analogues had modest activity, giving 30-50% protection to ATH8 cells infected with HIV. 2-Methyl (1d), 8-methyl (1h), and 2,N6-dimethyl (1e) substitution, as well as N1-oxide (21) formation, abolished the activity of the parent compound (1a). Several of these compounds, originally designed as agents for treating HIV in the central nervous system, were further investigated as substrates for adenosine deaminase (ADA). Kinetic experiments showed that ADA catalyzed the formation of the anti-HIV active inosine compound 1b from the N6-methyl analogue 1f in a quantitative manner. The anti-HIV activity of 1f and 1i was abolished when the ADA inhibitor, 2'-deoxycoformycin, was added to the test mixture. In contrast, the activity of 1f was significantly enhanced when ADA was added to the test system. These data indicate that 1f and 1i are prodrug forms of 1b in systems containing ADA.

  DOI：

  10.1021/jm00109a018
• 作为产物：
  描述：

  6-甲基腺素 在 咪唑 、 三乙基硼 、 四丁基氟化铵 、 氨 、 三正丁基氢锡 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 66.0h， 生成 [(4S,5R)-4-氟-5-(6-甲基氨基嘌呤-9-基)四氢呋喃-2-基]甲醇
  参考文献：
  名称：

  6-取代的2'，3'-二脱氧嘌呤核苷作为潜在的抗人免疫缺陷病毒制剂的合成与构效关系。

  摘要：

  为了研究2'，3'-二脱氧嘌呤核苷作为潜在的抗HIV药物的构效关系，已经合成了多种6-取代的嘌呤类似物，并在病毒感染和未感染的人外周血单核细胞中进行了研究。N6-甲基-2'，3'-二脱氧腺苷（D2MeA，7a）最初是通过2'，3'-O-双黄药3由腺苷合成的。由于该反应扩展到其他N6-取代的化合物失败，因此采用了全合成方法利用2'，3'-二脱氧核糖衍生物9合成其他嘌呤核苷。通过与N6-甲基腺嘌呤23缩合，由合适的碳水化合物24合成了N6-甲基-2'，3'-二脱氧腺苷，2'-氟阿拉伯呋喃糖基类似物32（D2MeFA）的酸稳定衍生物。N6-甲基衍生物（D2MeA）7a被证明是最有效的抗病毒药物之一。对于6个取代的化合物，其效力顺序为NHMe大于NH2大于Cl约N（Me）2大于SMe大于OH约NHEt大于SH大于NHBn约H。 2'，3'-二脱氧嘌呤核苷的6位可能决定这些化合物的抗病毒活性。发现酸

  DOI：

  10.1021/jm00168a006

文献信息

• Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2‘-β-Fluoro-2‘,3‘-dideoxyinosine
  作者：John S. Driscoll、Maqbool A. Siddiqui、Harry Ford,、James A. Kelley、Jeri S. Roth、Hiroaki Mitsuya、Masatoshi Tanaka、Victor E. Marquez

  DOI：10.1021/jm9509197

  日期：1996.1.1

  dimethylamino compounds are ca. 100 times more lipophilic than ddI or F-ddI. As expected, 2'-fluoro substitution protects the compounds from acid-catalyzed glycosylic cleavage. Only the hydroxylamino and nitro analogs underwent any nonenzymatic hydrolysis at pH 1.0 or 7.4. This reaction, however, results in hydrolysis of the group in the 6-position rather than glycosylic bond cleavage. ADA catalyzes

  合成并表征了一系列9-（2,3-二脱氧-2-氟-β-D-苏-五氟呋喃糖基）嘌呤（F-ddN）的6个取代氨基类似物，目的是发现可能是在治疗中枢神经系统中的HIV方面优于现有药物。这些化合物比目前批准的抗HIV药物具有更高的亲脂性，可以更好地渗透血脑屏障。随后腺苷脱氨酶（ADA）催化的这些前药在大脑中的水解可产生抗HIV药物9-（2,3-二脱氧-2-氟-β-D-苏-五呋喃糖基）次黄嘌呤（F- ddI）。由相应的6-氯类似物合成的新化合物包括F-ddN，其中含有甲基氨基，乙基氨基，二甲基氨基，羟基氨基，甲氧基氨基，苄氧基氨基，肼基，和在6-位的硝基取代基。在制备6-氯衍生物的过程中，以意外产物的形式分离了6-硝基类似物。在具有抗HIV活性的类似物中，乙氨基和二甲氨基化合物为约。亲脂性比ddI或F-ddI高100倍。如所预期的，2'-氟取代保护化合物免受酸催化的糖基裂解。在pH 1.0或7.4下，
• <i>In Vitro </i>and <i>in Vivo</i> Evaluation of 6-Azido-2‘,3‘-dideoxy-2‘-fluoro-β-<scp>d</scp>-arabinofuranosylpurine and <i>N</i><i>⁶</i>-Methyl-2‘,3‘-dideoxy-2‘-fluoro-β-<scp>d</scp>-arabinofuranosyladenine as Prodrugs of the Anti-HIV Nucleosides 2‘-F-ara-ddA and 2‘-F-ara-ddI
  作者：Tanya Koudriakova、Konstantine K. Manouilov、Kirupa Shanmuganathan、Lakshmi P. Kotra、F. Douglas Boudinot、Erica Cretton-Scott、Jean-Pierre Sommadossi、Raymond F. Schinazi、Chung K. Chu

  DOI：10.1021/jm960140c

  日期：1996.1.1

  In an effort to improve the pharmacokinetic properties and tissue distribution of 2'-F-ara-ddI, two lipophilic prodrugs, 6-azido-2',3'-dideoxy-2'-fluoro-beta-D-arabinofuranosyladenine (FAAddP, 4) and N-6-methyl-2',3'-dideoxy-2'-fluoro-beta-D-arabinofuranosyladenine (FMAddA, 5), were synthesized and their biotransformation was investigated in vitro and in vivo, in mice. Compounds 4 and 5 were synthesized via the intermediate 2. For the in vitro studies, FAAddP and FMAddA were incubated in mouse serum, liver homogenate, and brain homogenate. FAAddP was metabolized in liver homogenate by the reduction of the azido to the amino moiety followed by deamination, yielding 2'-F-ara-ddI. The conversion of FAAddP to 2'-F-ara-ddA was mediated by microsomal P-450 NADPH reductase system, as shown by the liver microsomal assay. FAAddP was also converted to 2'-F-ara-ddI at a slower rate in the brain than in the liver. FMAddA, however, was stable in brain homogenate and was slowly metabolized in the liver homogenate. Metabolic conversion of FMAddA in vitro was stimulated by the addition of adenosine deaminase. In the in vivo metabolism study, FAAddP underwent reduction to 2'-F-ara-ddA followed by deamination to 2'-F-ara-ddI. FMAddA did not result in increased brain delivery of 2'-F-ara-ddI in vivo, probably due to the slow conversion as observed in the in vitro studies. However, there was an increase in the half-life of 2'-F-ara-ddI produced from FMAddA. This report is the first example in the design of prodrugs using the azido group for adenine- and hypoxanthine-containing nucleosides. This interesting and novel approach can be extended to other antiviral and anticancer nucleosides.
• CHU, CHUNG K.;ULLAS, GILIYAR V.;JEONG, LAK S.;AHN, SOON K.;DOBOSZEWSKI, B+, J. MED. CHEM., 33,(1990) N, C. 1553-1561
  作者：CHU, CHUNG K.、ULLAS, GILIYAR V.、JEONG, LAK S.、AHN, SOON K.、DOBOSZEWSKI, B+

  DOI：——

  日期：——
• 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES
  申请人：THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce

  公开号：EP0540686B1

  公开（公告）日：1995-08-30
• US5336764A
  申请人：——

  公开号：US5336764A

  公开（公告）日：1994-08-09